BCIRG 005 main efficacy analysis: A phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC→T) in women with HER-2/neu negative axillary lymph node positive early breast cancer

This article has no abstract
Epistemonikos ID: a6c88117804774f2af7411aafd4d3727a0774cb2
First added on: Feb 28, 2025